Available Trials

Breast Cancer

  • STAR 16010

    A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer

    Available at 1 location

  • USOR 17082

    A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

    Available at 7 locations

  • USOR 17009

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxal plus a Reduced Dose of Capecitabine vs Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with Taxane

    Available at 7 locations

  • STAR 16195

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

    Available at 1 location

  • USOR 16023

    An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Recieved at Least Two Prior Treatments (IMMU-132-05)

    Available at 7 locations

  • USOR 16128

    Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

    Available at 5 locations

  • Alliance NSABP B-57-I

    Palbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

    Available at 1 location